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Abstract
Withaferin A (WA), a promising anticancer constituent of Ayurvedic medicinal plant Withania somnifera, inhibits growth of
MDA-MB-231 and MCF-7 human breast cancer cells in culture and MDA-MB-231 xenografts in vivo in association with
apoptosis induction, but the mechanism of cell death is not fully understood. We now demonstrate, for the first time, that
WA-induced apoptosis is mediated by reactive oxygen species (ROS) production due to inhibition of mitochondrial
respiration. WA treatment caused ROS production in MDA-MB-231 and MCF-7 cells, but not in a normal human mammary
epithelial cell line (HMEC). The HMEC was also resistant to WA-induced apoptosis. WA-mediated ROS production as well as
apoptotic histone-associated DNA fragment release into the cytosol was significantly attenuated by ectopic expression of
Cu,Zn-superoxide dismutase in both MDA-MB-231 and MCF-7 cells. ROS production resulting from WA exposure was
accompanied by inhibition of oxidative phosphorylation and inhibition of complex III activity. Mitochondrial DNA-deficient
Rho-0 variants of MDA-MB-231 and MCF-7 cells were resistant to WA-induced ROS production, collapse of mitochondrial
membrane potential, and apoptosis compared with respective wild-type cells. WA treatment resulted in activation of Bax
and Bak in MDA-MB-231 and MCF-7 cells, and SV40 immortalized embryonic fibroblasts derived from Bax and Bak double
knockout mouse were significantly more resistant to WA-induced apoptosis compared with fibroblasts derived from wild-
type mouse. In conclusion, the present study provides novel insight into the molecular circuitry of WA-induced apoptosis
involving ROS production and activation of Bax/Bak.
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Introduction
More than 40,000 women die from breast cancer each year in
the United States alone despite significant advances towards
targeted therapies and screening efforts [1]. Previous research has
identified some of the risk factors associated with breast cancer,
including family history, Li-Fraumeni syndrome, atypical hyper-
plasia of the breast, late-age at first full-term pregnancy, early
menarche, and late menopause [2,3]. Because some of these risk
factors are not easily adjustable (e.g., genetic predisposition), novel
strategies for reduction of breast cancer risk are clinically desirable.
This objective is partially fulfilled with selective estrogen-receptor
(ER) modulators (e.g., tamoxifen and raloxifene). Unfortunately,
this approach is effective only against ER-positive breast cancers
[4,5]. In addition, selective ER modulators have adverse side
effects including uterine cancer, thromboembolism, cataracts, and
perimenopausal symptoms [4]. Therefore novel agents that can
suppress growth of breast cancer cells regardless of ER status are
clinically attractive. Natural products have received increased
attention in recent years for the discovery of novel cancer
chemopreventive and therapeutic agents [6].
Withania somnifera L. Dunal (commonly known as Ashwagandha
or Indian winter cherry) has been used safely for thousands of
years in Ayurvedic medicine practice for the treatment of various
disorders. Withania somnifera exhibits a variety of pharmacological
effects in experimental animals [7–11]. For example, administra-
tion of 50 mg/kg Withania somnifera extract for 1 month conferred
cardioprotection against ischemia reperfusion injury in rats [8].
Markers of 6-hydroxydopamine-induced Parkinsonism were
reversible in rats after gavage of Withania somnifera [9].
Anticancer effects for Withania somnifera and its constituents have
also been described [12–26]. Anticancer effect of Withania somnifera
is attributed to withanolides including withaferin A (WA). WA was
shown to inhibit NF-kB-regulated gene expression in cancer cells
[14]. Treatment with WA inhibited human umbilical vein
endothelial cell sprouting at doses relevant to NF-kB inhibitory
activity [16]. Recent studies, including those from our laboratory,
have revealed proapoptotic effects of WA [19–21,23,24]. For
example, WA was shown to trigger Par-4 dependent apoptosis in
human prostate cancer cells [19]. Our own work has revealed that
WA inhibits growth of MDA-MB-231 and MCF-7 human breast
cancer cells by causing FOXO3a-Bim-dependent apoptosis [21].
We showed further that WA can trigger apoptosis and largely
inhibit cell migration/invasion of breast cancer cells even after
interleukin-6-induced activation of Signal Transducer and Acti-
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vator of Transcription 3 [26], which should be viewed as a
therapeutic advantage because this transcription factor is often
hyperactive in human breast cancers.
Despite these advances, however, the molecular circuitry of
WA-induced apoptosis is not fully defined. The present study fills
this gap in our knowledge using MDA-MB-231 (an ER-negative
cell line with mutant p53) and MCF-7 (an ER-positive cell line
with wild-type p53) human breast cancer cells and their respective
Rho-0 variants as models. We provide experimental evidence to
implicate reactive oxygen species (ROS) in WA-induced apoptosis.
Results
WA treatment causes ROS production in human breast
cancer cells
Because ROS are implicated in apoptosis induction by a variety
of natural anticancer agents [27], we questioned if proapoptotic
response to WA (structure of WA is shown in Fig. 1A) was
mediated by ROS generation. We tested this possibility using a
chemical probe (MitoSOX Red) that accumulates in mitochondria
and reacts with mitochondria-generated superoxide. As shown in
Figure 1. Withaferin A (WA) treatment causes reactive oxygen species (ROS) production in human breast cancer cells. (A) Chemical
structure of WA. (B) Flow cytometric analysis for MitoSOX Red fluorescence in DMSO-treated control and WA-treated MDA-MB-231 and MCF-7 cells
(4 h treatment). Results are shown as enrichment factor relative to DMSO-treated control (mean 6 SD, n=3). *P,0.05, significantly different
compared with DMSO-treated control by one-way ANOVA with Dunnett’s adjustment. (C) Fluorescence microscopy for MitoSOX Red fluorescence in
MDA-MB-231 and MCF-7 cells following 4 h treatment with DMSO or 2.5 mMWA. (D) Fluorescence microscopy for MitoSOX Red fluorescence in HMEC
following 4 h treatment with DMSO or 2.5 mM WA. (E) Representative EPR spectra in HMEC treated for 4 h with DMSO or 5 mM WA. All experiments
were repeated at least twice.
doi:10.1371/journal.pone.0023354.g001
ROS in WA-Induced Apoptosis
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Fig. 1B, WA treatment caused a dose-dependent increase in
MitoSOX Red fluorescence in MDA-MB-231 and MCF-7 cells.
In time-course kinetic experiments using 2.5 or 5 mM WA,
increase in MitoSOX Red fluorescence over dimethyl sulfoxide
(DMSO)-treated control was evident as early as 1–2 h after
treatment and persisted for at least 4–6 h (results not shown). ROS
generation by WA treatment in MDA-MB-231 and MCF-7 cells
was confirmed by fluorescence microscopy after staining the cells
with MitoSOX Red. As shown in Fig. 1C, DMSO-treated control
MDA-MB-231 and MCF-7 cells exhibited weak and diffuse
MitoSOX Red fluorescence. On the other hand, cells treated for
4 h with 2.5 mM WA were brightly stained with MitoSOX Red
suggesting superoxide generation. Moreover, MitoSOX Red-
associated fluorescence co-localized with the MitoTracker Green
signal indicating mitochondrial origin of WA-induced superoxide
generation (Fig. 1C). We next designed experiments to determine
susceptibility of a normal human mammary epithelial cell line
(HMEC) to ROS production by WA. Interestingly, HMEC
appeared resistant to ROS production by WA as judged by
fluorescence microscopy using MitoSOX Red (Fig. 1D) and
electron paramagnetic resonance (EPR) using a cell-permeable
spin probe 1-hydroxy-3-methoxy-carbonyl-2,2,5,5-tetramethylpyr-
rolidine (Fig. 1E). These results indicated that while WA treatment
caused ROS production in breast cancer cells, HMEC were
resistant to pro-oxidant effect of this agent. These results are
noteworthy because selectivity towards cancer cells is a highly
desirable feature for potential cancer chemopreventive agents.
Cu,Zn-Superoxide dismutase (Cu,Zn-SOD)
overexpression confers protection against WA-induced
ROS production and apoptosis
We designed experiments involving stable overexpression of
Cu,Zn-SOD to confirm the role of ROS in proapoptotic response to
WA. Protein level of Cu,Zn-SODwas about 11- and 3.2-fold higher
in MDA-MB-231 and MCF-7 cells, respectively, that were stably
transfected with the Cu,Zn-SOD expression plasmid in comparison
with empty vector-transfected control cells (Fig. 2A). Fig. 2B depicts
typical EPR spectra in MDA-MB-231 and MCF-7 cells transfected
with empty vector or vector encoding for Cu,Zn-SOD after 4 h
treatment with DMSO (control) or 5 mM WA. Radical signal
intensity was very weak in DMSO-treated cells. However, WA-
mediated increase in EPR signal intensity was suppressed
significantly by stable overexpression of Cu,Zn-SOD in both cell
lines (Fig. 2C). Empty vector-transfected cells exhibited significant
enrichment of histone-associated apoptotic DNA fragment release
into the cytosol upon treatment with WA when compared with
corresponding DMSO-treated controls (Fig. 2D). WA-mediated
apoptotic DNA fragmentation (Fig. 2D) and cleavage of procaspase-
3 (Fig. 2E) was markedly attenuated in cells with stable
overexpression of Cu,Zn-SOD (caspase-3 is not expressed in
MCF-7 cells). Consistent with EPR data (Fig. 1E), HMEC were
completely resistant to WA-induced histone-associated apoptotic
DNA fragment release into the cytosol (Fig. 2F). Two critical
conclusions are discernible from these experiments: (a) ROS play a
critical role in WA-induced apoptosis, and (b) HMEC are resistant
to apoptosis induction by WA treatment.
WA treatment inhibits oxidative phosphorylation in
human breast cancer cells
Because mitochondria are the major source of cellular superoxide,
which result from incomplete reduction of oxygen from 0.1–0.2% of
the ‘‘leaky’’ electrons that escape normal oxidative phosphorylation,
we next tested the possibility whether WA affected mitochondrial
bioenergetics. We measured oxygen consumption rate (OCR), an
indicator of oxidative phosphorylation (OXPHOS), in MDA-MB-
231 and MCF-7 cells (Fig. 3A). Basal OCR was markedly higher in
the MCF-7 cells in comparison with MDA-MB-231 (Fig. 3B). Both
cells showed a significant decrease in basal OCR after a 4 h treatment
with WA (Fig. 3B). However, WA-mediated decrease in basal
OXPHOS was more pronounced in the MDA-MB-231 cell line
compared with MCF-7. The spare and total reserve capacity for
OXPHOS in these two cell lines were examined by sequential
exposure to four metabolic inhibitors: oligomycin (identified by A in
Fig. 3A), carbonyl cyanide 4-trifluoromethoxyphenylhydrazone
(FCCP) (identified by B in Fig. 3A), 2-deoxyglucose (2-DG) (identified
by C in Fig. 3A), and rotenone (identified by D in Fig. 3A) [28].
Addition of oligomycin, which is an inhibitor of F1F0-ATPase
complex V, caused an inhibition of electron flow. As a consequence,
oligomycin addition decreased the OCR (Fig. 3A), which is an
indicator of oxygen linked ATP production. FCCP treatment allows
maximum oxygen consumption and gives a measure of spare
respiratory capacity. After injection of 2-DG, a glucose analog that
inhibits hexokinase and glucose utilization by glycolysis, cells showed
an increase in OCR as a result of activation of the total reserve
respiratory capacity. Finally, addition of the complex I inhibitor
rotenone arrested electron flow through the mitochondrial respira-
tory complexes and caused a dramatic decrease in the oxygen
consumption, as evidenced by the drop in the OCR in both cell lines
(Fig. 3A). Total reserve capacity for OXPHOS was measured by the
mean of points after 2-DG injection minus the mean of points after
rotenone injection. WA treatment resulted in a statistically significant
decrease in reserve OXPHOS in MDA-MB-231 and MCF-7 cells
especially at the 5 mM concentration (Fig. 3C).
Fig. 4A depicts basal extracellular acidification rate (ECAR), an
indicator of lactate production, for MDA-MB-231 and MCF-7
cells after treatment with DMSO (control) or WA (2.5 or 5 mM).
Basal lactate production in MDA-MB-231 and MCF-7 cells was
either not altered or slightly but significantly increased (MDA-MB-
231 cells at 2.5 mM WA dose) by WA treatment compared with
control. Oligomycin-induced ECAR (Fig. 4B) was only modestly
inhibited by 5 mM WA treatment in MDA-MB-231 cells only
(Fig. 4B). However, it is difficult to predict whether such a small
difference, albeit statistically significant, is biologically meaningful.
Because WA treatment caused a decrease in OXPHOS without
a compensating increase in glycolysis, a decrease in steady-state
levels of ATP was anticipated. However, steady-state levels of ATP
were unaffected by WA treatment in either cell line (Fig. 4C).
These observations suggest that WA treatment possibly causes a
decline in ATP utilization. Taken together, these results indicated
that OXPHOS was significantly inhibited by WA treatments in
both cell lines.
WA inhibits complex III activity in MDA-MB-231 cells
Because WA treatment exerted a relatively greater effect on
OXPHOS in the MDA-MB-231 cells, we used this cell line to
determine whether WA-mediated inhibition of OXPHOS was
accompanied by inhibition of mitochondrial respiratory chain
complex activities. Treatment of MDA-MB-231 cells with 5 mM
WA for 6 h resulted in a statistically significant decrease in the
activity of complex III, but not of complex I or complex II (Fig. 5).
A modest but significant increase in the activity of complex IV was
also observed in the WA-treated MDA-MB-231 cells relative to
DMSO-treated control (Fig. 5).
Rho-0 variants of MDA-MB-231 and MCF-7 cells are
resistant to WA-induced apoptosis
To get further support for the contribution of mitochondrial
ROS in WA-mediated apoptosis, we generated Rho-0 variants of
ROS in WA-Induced Apoptosis
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MDA-MB-231 and MCF-7 cells as described by us previously
[29]. Of the 13 polypeptides encoded by the mitochondrial DNA,
many are integral components of the mitochondrial respiratory
chain complexes [30]. The Rho-0 cells lack OXPHOS but their
survival is dependent on ATP derived from anaerobic glycolysis.
The Rho-0 variants of MDA-MB-231 and MCF-7 cells have
significantly diminished levels of complex I and III activity [29]. As
expected, exposure of wild-type MDA-MB-231 and MCF-7 cells
Figure 2. Cu,Zn-Superoxide dismutase (Cu,Zn-SOD) overexpression attenuates withaferin A (WA)-induced apoptosis in MDA-MB-
231 and MCF-7 cells. (A) Immunoblotting for Cu,Zn-SOD using lysates from MDA-MB-231 or MCF-7 cells stably transfected with empty vector (lane
1) or vector encoding for Cu,Zn-SOD (lane 2). (B) Representative EPR spectra in MDA-MB-231 and MCF-7 cells stably transfected with empty vector or
vector encoding for Cu,Zn-SOD and treated for 4 h with DMSO or 5 mM WA. (C) Quantitation of EPR signal intensity in MDA-MB-231 and MCF-7 cells
transfected with empty vector or vector encoding for Cu,Zn-SOD and treated for 4 h with DMSO or 5 mM WA. Results shown are mean 6 SD (n= 3).
(D) Histone-associated DNA fragment release into the cytosol (a measure of apoptosis) in MDA-MB-231 and MCF-7 cells transfected with empty
vector or vector encoding for Cu,Zn-SOD and treated for 24 h with DMSO or WA. Results shown are mean 6 SD (n=3). (E) Immunoblotting for
cleaved caspase-3 using lysates from MDA-MB-231 cells stably transfected with empty vector or vector encoding for Cu,Zn-SOD and treated for 24 h
with DMSO or WA. (F) Histone-associated DNA fragment release into the cytosol in HMEC treated for 24 h with DMSO or WA. Results shown are mean
6 SD (n= 3). Significantly different (P,0.05) compared with acontrol (DMSO-treated), and b between groups at each dose by one-way ANOVA
followed by Bonferroni’s adjustment. For data in panels C,D, and F, data are shown as enrichment factor relative to DMSO-treated control. All
experiments were repeated at least twice.
doi:10.1371/journal.pone.0023354.g002
ROS in WA-Induced Apoptosis
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to WA for 4 h resulted in a statistically significant enrichment of
MitoSOX Red fluorescence over DMSO-treated control (Fig. 6A).
ROS production was greatly diminished in the Rho-0 cells by a
similar treatment with WA (Fig. 6A). WA treatment (5 mM, 24 h)
caused a significant increase in apoptotic DNA fragmentation in
wild-type MDA-MB-231 and MCF-7 cells but not in the Rho-0
variants (Fig. 6B).
We used JC-1 to determine the effect of WA treatment on
mitochondrial membrane potential. Cationic JC-1 enters mito-
chondria due to negative charge established by the intact
Figure 3. Withaferin A (WA) treatment inhibits oxidative phosphorylation (OXPHOS) inMDA-MB-231 andMCF-7 cells. (A) Pharmacologic
profiling of oxygen consumption rate (OCR), an indicator of OXPHOS, in MDA-MB-231 and MCF-7 cells following 4 h treatment with DMSO (control)
or the indicated concentrations of WA. After measurement of basal OCR, the cells were treated with a series of metabolic inhibitors, including
oligomycin (injection A); FCCP (injection B); 2-DG (injection C); and rotenone (injection D) at the indicated times. (B) Effect of WA treatment on basal
OCR in MDA-MB-231 and MCF-7 cells. Basal OCR was calculated using the difference between the mean of time points prior to injection A (#1–#4)
and after injection D (#14 to #16; rotenone-sensitive) ( X1{4{ X14{16). (C) Effect of WA treatment on total reserve respiration capacity in MDA-MB-
231 and MCF-7 cells. Total reserve respiration capacity was calculated using the mean of the time points after injection C (#11–#13) minus the mean
of time points after injection D (#14–#16) ( X11{13{ X14{16). Data shown are mean 6 SEM of three independent experiments, each performed in
triplicate. *P,0.05; **P,0.01; and ***P,0.001, significantly different compared with control by one-way ANOVA with Dunnett’s adjustment.
doi:10.1371/journal.pone.0023354.g003
ROS in WA-Induced Apoptosis
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mitochondrial membrane potential. Mitochondria of healthy cells
are characterized by red fluorescence due to accumulation of J-
aggregates. In apoptotic cells, JC-1 dye accumulates in the
cytoplasm in monomeric form (green fluorescence) due to collapse
of the mitochondrial membrane potential. WA treatment caused a
dose-dependent accumulation of monomeric JC-1 in wild-type
MDA-MB-231 and MCF-7 cells, but not in their respective Rho-0
variants (Fig. 6C). These results indicated that ROS acted
upstream of mitochondrial membrane potential collapse in WA-
induced apoptosis.
WA treatment causes activation of Bak and Bax
Results presented thus far establish a critical role for ROS in
proapoptotic effect of WA, but do not shed light on mechanisms
Figure 4. Withaferin A (WA) treatment fails to alter acidification rate (lactate production)and steady-state levels of ATP. (A) Effect of
WA treatment on basal extracellular acidification rate (ECAR), a measure of lactate production, in MDA-MB-231 and MCF-7 cells following 4 h
treatment with DMSO (control) or the indicated concentrations of WA. (B) Effect of WA treatment on oligomycin-induced (oligo-induced) ECAR in
MDA-MB-231 and MCF-7 cells. Results shown are mean6 SEM of three independent experiments, each performed in triplicate. (C) Steady-state levels
of ATP in MDA-MB-231 and MCF-7 cells treated with DMSO (control) or the indicated concentrations of WA in the absence or presence of the
metabolic inhibitors. Results shown are mean 6 SEM of combination of three independent experiments, each performed in quadruplicate. *P,0.05;
**P,0.01; and ***P,0.001, significantly different compared with control by one-way ANOVA with Dunnett’s adjustment (Panels A and B) or Student’s
t-test (panel C).
doi:10.1371/journal.pone.0023354.g004
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downstream of ROS production in the execution of WA-induced
apoptosis. Because oxidative stress was previously shown to cause
activation (conformational change) of Bax [29,31], we tested the
possibility of ROS-dependent Bax activation in our model. We
tested this possibility by examining the effect of WA treatment on
activation of Bak and Bax by immunofluorescence microscopy
using antibodies that recognize only activate forms of these
proteins. DMSO-treated control MDA-MB-231 (Fig. 7A) and
MCF-7 cells (Fig. 7B) exhibited very weak activate Bak- or Bax-
associated immunofluorescence. Treatment of MDA-MB-231 and
MCF-7 cells with 2.5 mM (Fig. 7A-B) and 5 mM WA (results not
shown) for 24 h resulted in enrichment of the activate Bak and Bax
proteins. These results indicated that WA treatment caused
activation of both Bax and Bak in MDA-MB-231 and MCF-7
cells. On the other hand, HMEC were resistant to Bak activation
by WA, although a slight increase in active Bax-associated green
fluorescence over DMSO-treated control was visible in WA-
treated HMEC (Fig. 7C). Furthermore, when ROS production in
the MDA-MB-231 cells was suppressed by overexpression of
Cu,Zn-SOD, level of active Bak, but not Bax, was markedly
suppressed (Fig. 8A). These results indicated that while WA
treatment caused activation of both Bax and Bak, only Bak
activation was dependent on ROS production.
Bak and Bax are essential for apoptotic response to WA
We utilized siRNA to further probe into the role of Bax and Bak
in regulation of WA-induced apoptosis. Level of Bak and Bax
protein was decreased by 60%–70% in MCF-7 cells transiently
transfected with Bak and Bax-targeted siRNAs (Fig. 8B). WA
treatment (24 h) caused a dose-dependent and statistically
significant increase in histone-associated DNA fragment release
into the cytosol in cells transfected with the control nonspecific
siRNA. On the other hand, combined knockdown of Bax and Bak
proteins conferred partial but significant protection against WA-
induced DNA fragmentation (Fig. 8C). We reasoned that partial
protection against WA-induced DNA fragmentation by combined
RNA interference of Bax and Bak could be attributable to
incomplete knockdown of these proteins. To address this question,
we used SV40 immortalized mouse embryonic fibroblasts (MEF)
derived from wild-type (WT) and Bax and Bak double knockout
mice (DKO). As can be seen in Fig. 8D, WA treatment resulted in
appearance of apoptotic cells with condensed and fragmented
DNA in WT cells but not in DKO. Consistent with these
observations, DKO cells were nearly completely resistant to WA-
induced apoptotic DNA fragmentation (Fig. 8E). These results
indicated that WA-induced apoptosis was regulated by Bax and
Bak.
Discussion
The primary objective of the present study was to gain insight
into the mechanism by which WA, a highly promising herbal
medicine constituent [32], triggers apoptosis in human breast
cancer cells. We show that WA-induced apoptosis in human breast
cancer cells is mediated by mitochondria-derived ROS as
evidenced by flow cytometric and microscopic measurements
using a chemical probe and EPR using a spin probe. ROS
production by WA treatment is apparently not influenced by the
p53 or ER status because pro-oxidant effect of WA is evident in
both MDA-MB-231 and MCF-7 cells. Because stable overexpres-
sion of Cu,Zn-SOD significantly blunts apoptotic cell death
response to WA, it is reasonable to conclude that the signal for
Figure 5. WA treatment inhibits complex III activity in MDA-MB-231 breast cancer cells. Mitochondrial complex enzyme activities were
determined using lysates from MDA-MB-231 cells treated for 6 h with DMSO or 5 mM WA. Results shown are mean 6 SD (n=3). *P,0.05; **P,0.01,
significantly different compared with control by Student’s t-test.
doi:10.1371/journal.pone.0023354.g005
ROS in WA-Induced Apoptosis
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initiation of WA-induced cell death is most likely provided by the
ROS. Even though ROS generation by WA treatment was
documented previously in HL-60 leukemia cells [20], the present
study is the first to demonstrate that WA-induced ROS production
is accompanied by dysfunction of mitochondria reflected by
inhibition of both basal and reserve OXPHOS and inhibition of
complex III activity. Resistance of Rho-0 cells to WA-mediated
ROS generation as well as apoptosis provides further support to
our contention that proapoptotic response to this agent is initiated
by the mitochondria-derived ROS. Translational implication of
these findings is that the anti-cancer response to WA may be
compromised in the presence of antioxidants. However, the exact
topology of mitochondrial superoxide production in WA-treated
cells remains to be elucidated. Inhibition of OXPHOS at complex
III is often associated with superoxide production within the
mitochondrial matrix or the intermembrane space [33]. Superox-
ide generated in the intermembrane space would be susceptible to
Cu,Zn-SOD which is found in this compartment.
It is interesting to note that despite significant inhibition of
OXPHOS in both MDA-MB-231 and MCF-7 cells, steady-state
levels of ATP are not altered by WA treatment in either cell line.
Because rate of lactate production is comparable in control and
WA-treated cells, it is reasonable to argue that maintenance of the
ATP levels is not due to a compensatory increase in the glycolysis.
Steady-state levels of ATP are regulated not only by its synthesis
but also utilization by a variety of reactions including synthesis of
Figure 6. Rho-0 variants of MDA-MB-231 and MCF-7 cells are resistant to withaferin A (WA)-mediated apoptosis. (A) MitoSOX Red
fluorescence (a measure of ROS production) in wild-type (WT) and Rho-0 variants of MDA-MB-231 and MCF-7 cells following 4 h treatment with
DMSO (control) or WA. Enrichment of MitoSOX Red fluorescence relative to DMSO-treated wild-type cells is shown for both MDA-MB-231 and MCF-7
cells. (B) Histone-associated DNA fragment release into the cytosol in wild-type and Rho-0 variants of MDA-MB-231 and MCF-7 cells following 24 h
treatment with DMSO or WA. Enrichment relative to DMSO-treated wild-type cells is shown for both MDA-MB-231 and MCF-7 cells. (C) Analysis of
mitochondrial membrane potential (monomeric JC-1-associated green fluorescence) in wild-type and Rho-0 variants of MDA-MB-231 and MCF-7 cells
following 24 h treatment with DMSO or WA. Enrichment relative to DMSO-treated wild-type cells is shown for both MDA-MB-231 and MCF-7 cells.
Results shown are mean6 SD (n=3). Significantly different (P,0.05) compared with corresponding acontrol (DMSO-treated) and bbetween groups at
each dose by one-way ANOVA followed by Bonferroni’s multiple comparison test. Each experiment was repeated at least twice.
doi:10.1371/journal.pone.0023354.g006
ROS in WA-Induced Apoptosis
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macromolecules, and sodium and calcium cycling across the
plasma membrane [34,35]. Therefore, the possibility that WA
treatment causes a decrease in bioenergetic demand for ATP
cannot be ruled out. Further studies are needed to systematically
explore this possibility.
Another critical objective of the present study was to gain
insight into the mechanism downstream of ROS generation in
execution of WA-mediated cell death. The Bcl-2 family proteins
have emerged as critical regulators of the cell death by functioning
as either inhibitors (e.g., Bcl-2 and Bcl-xL) or facilitators (e.g., Bax
and Bak) of apoptosis [36,37]. We have shown previously that WA
treatment causes a modest increase in the levels of Bax and/or Bak
proteins in MDA-MB-231 and MCF-7 cells [21]. WA-mediated
induction of Bax in acute T leukemia cell line (MOLT-4) has also
been reported [24]. To the contrary, induction of Bax upon
treatment with WA was not evident in U937 human leukemia cells
[23]. While involvement of Bax in WA-induced apoptosis seems
cell line-specific, none of these studies examined the effect of WA
treatment on activation of Bax and Bak. This is important because
activation (conformational change) and mitochondrial transloca-
tion of Bax is required for its proapoptotic activity in response to
different treatments including hyperoxia [31,37,38]. The present
study indicates that WA treatment causes activation of both Bak
and Bax. Moreover, both Bax and Bak seem to contribute to
apoptosis induction by WA as evidenced by the results using MEF.
In conclusion, the present study demonstrates that WA
treatment inhibits basal and reserve OXPHOS, but not glycolysis,
leading to ROS production and apoptotic DNA fragmentation.
Translational implication of these findings is that the anticancer
effect of WA may be compromised in the presence of anti-
oxidants. This is a strong possibility because cell death response to
WA is significantly attenuated by overexpression of Cu,Zn-SOD.
Methods
Reagents
WA (purity ,96%) was purchased from Chromadex (Irvine,
CA), dissolved in DMSO, and diluted with complete media
immediately before use. The 49,6-diamidino-2-phenylindole
(DAPI), FCCP, oligomycin, 2-DG, and rotenone were purchased
from Sigma-Aldrich (St. Louis, MO). MitoSOX Red, Mito-
Tracker Green, and MitoTracker Red were purchased from
Invitrogen-Life Technologies (Carlsbad, CA). Cell-permeable spin
probe 1-hydroxy-3-methoxy-carbonyl-2,2,5,5-tetramethylpyrroli-
dine was purchased from Noxygen Science Transfer and
Diagnostics (Elzach, Germany). Anti-actin antibody was from
Sigma-Aldrich; anti-activated Bak and anti-Cu,Zn-SOD antibod-
ies were from EMD Chemicals (Gibbstown, NJ); and anti-
activated Bax (6A7) antibody was from BD Biosciences (San
Diego, CA).
Cell lines
The MDA-MB-231 and MCF-7 cells were purchased from the
American Type Culture Collection (Manassas, VA) and main-
tained as described by us previously [29,39]. The Rho-0 variants
of MDA-MB-231 and MCF-7 cells were generated and main-
tained as described by us previously [29]. The MDA-MB-231 or
MCF-7 cells were transfected with empty pcDNA3.1 vector or
pcDNA3.1 vector encoding for Cu,Zn-SOD using FuGENE6.
Cells stably overexpressing Cu,Zn-SOD were selected by culture
in medium supplemented with 800 mg/mL of G418 over a period
of 8 weeks. The HMEC were maintained in serum-free Mammary
Epithelial Growth Medium (Clonetics, San Diego, CA). The SV40
immortalized MEF from WT and DKO mice were maintained as
described by us previously [40].
Detection of ROS
ROS production was measured by flow cytometry or immuno-
fluorescence microscopy following staining with MitoSOX Red
and EPR. For flow cytometric analysis, cells were treated with
DMSO (control) or desired concentrations of WA for specified
time intervals and then incubated with 5 mM MitoSOX Red for
30 min. Cells were collected, washed with phosphate-buffered
saline (PBS) and fluorescence was detected using a Coulter Epics
XL Flow Cytometer. For immunofluorescence microscopy, cells
Figure 7. Withaferin A (WA) treatment causes activation of Bak
and Bax in breast cancer cells. Immunofluorescence microscopy for
active Bak and Bax in MDA-MB-231 (A), MCF-7 (B), and HMEC (C)
following 24 h treatment with DMSO (control) or 2.5 mM WA. Each
experiment was repeated at least twice.
doi:10.1371/journal.pone.0023354.g007
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Figure 8. Bak and Bax are required for withaferin A (WA)-induced apoptosis. (A) Immunofluorescence microscopy for active Bak and Bax in
MDA-MB-231 cells stably transfected with empty vector or vector encoding for Cu,Zn-SOD and treated for 24 h with DMSO or WA. (B)
Immunoblotting for Bak and Bax using lysates from MCF-7 cells transiently transfected with a control nonspecific small interfering RNA (siRNA; lane 1)
or Bax- or Bak-targeted siRNA (lane 2). (C) Histone-associated DNA fragment release into the cytosol in siRNA-transfected MCF-7 cells following 24 h
treatment with DMSO (control) or the indicated concentrations of WA. Results are shown as enrichment factor relative to DMSO-treated control siRNA
transfected cells (mean 6 SD, n= 3). (D) Fluorescence microscopic analysis for apoptotic cells with condensed and fragmented DNA (DAPI assay) in
SV40 immortalized mouse embryonic fibroblasts (MEF) derived from wild-type (WT) and Bax and Bak double knockout (DKO) mice and treated for
24 h with DMSO (control) or 5 mM WA. (E) Histone-associated DNA fragment release into the cytosol in WT and DKO treated for 24 h with DMSO
(control) or the indicated concentrations of WA. Results are shown as enrichment factor relative to DMSO-treated wild-type MEF (mean 6 SD, n= 3).
Significantly different (P,0.05) compared with aDMSO-treated control siRNA-transfected MCF-7 cells (panel C) or DMSO-treated WT MEF (panel E),
and bbetween groups at each dose by one-way ANOVA followed by Bonferroni’s test. Similar results were observed in two independent experiments.
doi:10.1371/journal.pone.0023354.g008
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were plated on coverslips and allowed to attach by overnight
incubation. Cells were then treated with DMSO (control) or WA
followed by incubation with 2.5 mM MitoSOX Red for 30 min at
37uC. Cells were then treated for 15 min with 200 nM
MitoTracker Green to stain mitochondria. After washing with
PBS, cells were fixed with 2% paraformaldehyde for 1 h at room
temperature and examined under a Leica fluorescence microscope
at 1006 objective magnification. For EPR studies, one million
cells were plated in 10-cm dish and exposed to DMSO or 5 mM
WA. Cells were collected by scraping, centrifuged, and the pellet
was re-suspended in 100 mL of Krebs HEPES buffer (pH 7.4).
EPR was performed using a Bruker eScan Table Top EPR
spectrometer. Briefly, samples were exposed to spin probe at a
final concentration of 200 mM and immediately loaded into 50 mL
glass capillaries and placed into a temperature and gas-controlled
EPR cavity for 10 min. Control samples, in the absence of cell
sample, were conducted to determine the auto-oxidation of the
spin probe under our experimental conditions and were subtracted
from the signal intensity values. The EPR instrument settings were
as follows: field sweep 50G; microwave frequency 9.78 GHz;
microwave power 20 mW; modulation amplitude 2G; conversion
time 327 ms; time constant 655 ms; and receiver gain 16105. To
minimize the deleterious effects of adventitious metals, all buffers
were treated with Chelex resin.
Immunoblotting
Preparation of total lysates from control or WA-treated cells was
done as described by us previously [21,26]. Western blotting was
done as described by us previously [21,26]. Immunoreactive bands
were visualized using enhanced Chemiluminescence methods.
Detection of apoptosis
Apoptosis induction was assessed by quantitation of histone-
associated DNA fragment release into the cytosol using an ELISA
kit (Roche Applied Science, Indianapolis, IN) or DAPI assay. For
DAPI assay, cells were plated on glass coverslips in 12-well plates.
After 24 h incubation, cells were treated with DMSO or 5 mM
WA for an additional 24 h and fixed in 2% paraformaldehyde for
1 h at room temperature. Cells were permeabilized with 0.5%
Triton X-100 for 10 min, and stained with 10 ng/mL DAPI for
10 min at room temperature. Apoptotic cells were counted under
a Leica DC 300F fluorescence microscope.
Real time measurements of OXPHOS and glycolysis
The OCR and ECAR, which respectively are the indicators of
OXPHOS and glycolysis, were measured in real-time using a
Seahorse Bioscience XF24 Extracellular Flux Analyzer (Billerica,
MA) [41]. Cells were seeded in XF24-well microplate (46104
cells/well), and incubated at 37uC for 20–24 h. Cells were washed
with unbuffered Dulbecco’s modified essential medium (DMEM),
and incubated for 1 h at 37uC without CO2 in 750 mL of
unbuffered DMEM (pH 7.4) supplemented with GlutaMax-1
(final concentration 2 mM), sodium pyruvate (final concentration
1 mM), glucose (final concentration 25 mM), sodium chloride
(final concentration 32 mM) and phenol red. After determining
the basal rates of OCR and ECAR, a pharmacological profiling of
mitochondrial function was performed by injection of four
compounds that affect bioenergetics, including: oligomycin (final
concentration 1 mM) at injection A, FCCP (final concentration
300 nM) at injection B, 2-DG (final concentration 100 mM) at
injection C, and rotenone (final concentration 1 mM) at injection
D. After completion of the experiment, cells were trypsinized and
counted for normalization. The OCR was analyzed using an
algorithm described by Gerencser et al. [42]. ATP measurements
were done using the ATPlite kit from Perkin Elmer (Waltham,
MA). This method is based on the amount of light produced by an
ATP-dependent luciferase reaction. Briefly cells (46104 cells/well)
were grown overnight in 96-well black microplate and treated
separately in quadruplicate with the indicated test compounds for
45 min. The cells were lysed by adding 50 mL of mammalian cell
lysis solution followed by addition of 50 mL of substrate solution.
Light produced was measured using a Biotek Synergy 2 Plate
Reader (Winooski, VT) and compared to a series of ATP
standards.
Measurements of mitochondrial complex activities and
membrane potential
Control and WA-treated MDA-MB-231 cell pellets were frozen
and thawed three times to lyse plasma membrane. Activities were
detected spectrophotometrically as previously described [43].
Complex I activity was detected by the rotenone sensitive
oxidation of NADH. Complex II and III activities were detected
by the oxidation/reduction of ubiquinol. Complex IV activity was
detected by the oxidation of cytochrome c. All activities were
normalized to the activity of the matrix enzyme citrate synthase.
The effect of WA treatment on mitochondrial membrane potential
was determined using JC-1 assay kit from Invitrogen-Life
Technologies as instructed by the supplier. The wild-type and
Rho-0 variants of MDA-MB-231 and MCF-7 cells were allowed to
attach by overnight incubation, exposed to WA for specified time,
and collected by trypsinization. The cells were incubated with
medium containing JC-1 (2 mM) for 15 min at 37uC. The cells
were washed and re-suspended in PBS, and fluorescence was
measured using a Coulter Epics XL Flow Cytometer.
Immunofluorescence microscopy for detection of
activate Bax and Bak
Desired cells treated with DMSO or WA (24 h) were exposed to
200 nM MitoTracker Red for 30 min, and fixed with parafor-
maldehyde following permeabilization with Triton X-100. Next,
the cells were treated with PBS containing 0.5% bovine serum
albumin and 0.15% glycine for 1 h and incubated with anti-
activate Bak or Bax antibody overnight at 4uC. The cells were
incubated with Alexa Fluor 488-conjugated secondary antibody
for 1 h at room temperature, and examined under a Leica DC
300F fluorescence microscope.
RNA interference
MCF-7 cells were seeded in six-well plates and transfected at
50% confluency with 100 nM of control non-specific siRNA or
Bak- and Bax-targeted siRNAs using OligofectAMINE. Twenty-
four hours after transfection, the cells were treated with DMSO
(control) or specified concentrations of WA for 24 h. The cells
were then collected and processed for immunoblotting and
analysis of cytoplasmic histone-associated DNA fragmentation.
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